Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Mari A. Mino-Kenudson

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9092-2265; OpenAlex author ID A5072389805. Sources: OpenAlex.

Their work

Papers
40 (first author 1, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
150
Papers, trials and grants by year

2011: 2 papers · 2012: 2 papers · 2013: 1 paper · 2014: 1 paper · 2015: 1 paper · 2016: 2 papers · 2017: 5 papers · 2018: 1 paper · 2019: 1 paper · 2020: 6 papers · 2021: 4 papers · 2022: 4 papers · 2023: 2 papers · 2024: 4 papers · 2025: 2 papers · 2026: 2 papers

Papers 40

  1. GLIS3 marks a neural-like progenitor cell state that drives metastasis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.celrep.2026.117314↗
  2. Spatiotemporal metabolic networks in a preclinical model of pancreatic cancer and associated cachexia. Co-author DOI 10.1038/s41467-026-77745-0↗
  3. The Pdgfd-Pdgfrb axis orchestrates tumor-nerve crosstalk in pancreatic cancer Co-author DOI 10.1101/2025.08.26.672505↗
  4. Collagen XVII Promotes Pancreatic Ductal Adenocarcinoma Tumor Growth through Regulation of PIK3R5. Co-author DOI 10.1158/2767-9764.crc-24-0392↗
  5. Immunofluorescence profiling of collagen subtypes is a predictor of treatment outcomes in pancreatic cancer. Co-author DOI 10.1016/j.jphotobiol.2023.112811↗
  6. Spatially resolved analysis of pancreatic cancer identifies therapy-associated remodeling of the tumor microenvironment. Co-author DOI 10.1038/s41588-024-01890-9↗
  7. Does CT overestimate extra-pancreatic perineural invasion in patients with pancreatic ductal adenocarcinoma following neoadjuvant chemoradiation therapy? Co-author DOI 10.1093/bjr/tqae001↗
  8. Dynamic Evolution of Fibroblasts Revealed by Single-Cell RNA Sequencing of Human Pancreatic Cancer. Co-author DOI 10.1158/2767-9764.crc-23-0489↗
  9. Ornithine aminotransferase supports polyamine synthesis in pancreatic cancer. Co-author DOI 10.1038/s41586-023-05891-2↗
  10. Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3+ Cancer Cells in Locally Advanced Pancreatic… Co-author DOI 10.1158/1078-0432.ccr-22-1630↗
  11. Remediating Desmoplasia with EGFR-Targeted Photoactivable Multi-Inhibitor Liposomes Doubles Overall Survival in Pancreatic Cancer. Co-author DOI 10.1002/advs.202104594↗
  12. Single-nucleus and spatial transcriptome profiling of pancreatic cancer identifies multicellular dynamics associated with neoadjuvant treatment. Co-author DOI 10.1038/s41588-022-01134-8↗
  13. A Combination of Biochemical and Pathological Parameters Improves Prediction of Postresection Survival After Preoperative Chemotherapy in Pancreatic Cancer: Th… Co-author DOI 10.1097/sla.0000000000004143↗
  14. Reassessment of the Optimal Number of Examined Lymph Nodes in Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000004552↗
  15. mAb Das-1 identifies pancreatic ductal adenocarcinoma and high-grade pancreatic intraepithelial neoplasia with high accuracy. Last author DOI 10.1016/j.humpath.2021.01.003↗
  16. Reproducibility and prognostic significance of area of residual tumor (ART) in post-neoadjuvant resections of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2021.09.006↗
  17. Adaptation of pancreatic cancer cells to nutrient deprivation is reversible and requires glutamine synthetase stabilization by mTORC1. Co-author DOI 10.1073/pnas.2003014118↗
  18. Transcriptomic Analysis of Laser Capture Microdissected Tumors Reveals Cancer- and Stromal-Specific Molecular Subtypes of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-20-1039↗
  19. Objective assessment of tumor regression in post-neoadjuvant therapy resections for pancreatic ductal adenocarcinoma: comparison of multiple tumor regression g… Last author DOI 10.1038/s41598-020-74067-z↗
  20. Single-nucleus and spatial transcriptomics of archival pancreatic cancer reveals multi-compartment reprogramming after neoadjuvant treatment Co-author DOI 10.1101/2020.08.25.267336↗
  21. Microscopic size measurements in post-neoadjuvant therapy resections of pancreatic ductal adenocarcinoma (PDAC) predict patient outcomes. Last author DOI 10.1111/his.14067↗
  22. Neoplastic-Stromal Cell Cross-talk Regulates Matrisome Expression in Pancreatic Cancer. Co-author DOI 10.1158/1541-7786.mcr-20-0439↗
  23. Does Site Matter? Impact of Tumor Location on Pathologic Characteristics, Recurrence, and Survival of Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-020-08354-4↗
  24. FOLFIRINOX Versus Gemcitabine-based Therapy for Pancreatic Ductal Adenocarcinoma: Lessons from Patient-derived Cell Lines. Co-author DOI 10.21873/anticanres.14355↗
  25. Area of residual tumor (ART) can predict prognosis after post neoadjuvant therapy resection for pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-019-53801-2↗
  26. Investigation of HNF-1B as a diagnostic biomarker for pancreatic ductal adenocarcinoma. Last author DOI 10.1186/s40364-018-0139-6↗
  27. Critical role for arginase 2 in obesity-associated pancreatic cancer. Co-author DOI 10.1038/s41467-017-00331-y↗
  28. Assessment of the Utility of Laparoscopy and Peritoneal Cytology in the Staging of Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000000866↗
  29. Multi-institutional Validation Study of the American Joint Commission on Cancer (8th Edition) Changes for T and N Staging in Patients With Pancreatic Adenocarc… Last author DOI 10.1097/sla.0000000000001763↗
  30. Does Size Matter in Pancreatic Cancer?: Reappraisal of Tumour Dimension as a Predictor of Outcome Beyond the TNM. Co-author DOI 10.1097/sla.0000000000001837↗
  31. Tumor engraftment in patient-derived xenografts of pancreatic ductal adenocarcinoma is associated with adverse clinicopathological features and poor survival. Co-author DOI 10.1371/journal.pone.0182855↗
  32. Phosphatase PPM1A is a novel prognostic marker in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.humpath.2016.05.002↗
  33. Regulation of GLI Underlies a Role for BET Bromodomains in Pancreatic Cancer Growth and the Tumor Microenvironment. Co-author DOI 10.1158/1078-0432.ccr-15-2068↗
  34. Circulating tumor cells found in patients with localized and advanced pancreatic cancer. Co-author DOI 10.1097/mpa.0000000000000324↗
  35. Enhanced primary tumor delineation in pancreatic adenocarcinoma using ultrasmall super paramagnetic iron oxide nanoparticle-ferumoxytol: an initial experience … First author DOI 10.2147/ijn.s59788↗
  36. Accurate prediction of nodal status in preoperative patients with pancreatic ductal adenocarcinoma using next-gen nanoparticle. Co-author DOI 10.1593/tlo.13400↗
  37. Intraductal papillary mucinous neoplasms: does a family history of pancreatic cancer matter? Co-author DOI 10.1016/j.pan.2012.05.011↗
  38. Pancreatic ductal adenocarcinoma: long-term survival does not equal cure. Co-author DOI 10.1016/j.surg.2012.05.020↗
  39. Phase I study of preoperative short-course chemoradiation with proton beam therapy and capecitabine for resectable pancreatic ductal adenocarcinoma of the head. Co-author DOI 10.1016/j.ijrobp.2009.10.061↗
  40. Plectin-1 as a novel biomarker for pancreatic cancer. Co-author DOI 10.1158/1078-0432.ccr-10-0999↗

Closest collaborators

The 25 strongest of 150 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Carlos F. Fernandez-del Castillo · 19 shared papers, 2011–2025 · strength 1.69
  2. Keith D. Lillemoe · 15 shared papers, 2012–2025 · strength 1.39
  3. Andrew Louis Warshaw · 12 shared papers, 2011–2025 · strength 0.99
  4. David Tsai Ting · 7 shared papers, 2020–2025 · strength 0.91
  5. Andrew Scott Liss · 9 shared papers, 2015–2025 · strength 0.86
  6. Cristina Rosa Ferrone · 10 shared papers, 2012–2024 · strength 0.80
  7. Motaz Qadan · 6 shared papers, 2020–2024 · strength 0.74
  8. Theodore Sunki Hong · 7 shared papers, 2011–2025 · strength 0.73
  9. Thomas P. Hank · 6 shared papers, 2020–2025 · strength 0.72
  10. Jennifer Yon-Li Wo · 5 shared papers, 2020–2025 · strength 0.63
  11. William L. Hwang · 4 shared papers, 2020–2026 · strength 0.59
  12. Jimmy A. Guo · 4 shared papers, 2020–2026 · strength 0.59
  13. Tyler Jacks · 4 shared papers, 2020–2026 · strength 0.59
  14. Nada Y. Kalaany · 4 shared papers, 2017–2026 · strength 0.57
  15. Nicholas J Caldwell · 3 shared papers, 2024–2026 · strength 0.52
  16. Dennis H. Gong · 3 shared papers, 2024–2026 · strength 0.52
  17. Carina Shiau · 3 shared papers, 2024–2026 · strength 0.52
  18. Min-Sik Lee · 3 shared papers, 2021–2026 · strength 0.52
  19. Jon Michael Harrison · 3 shared papers, 2022–2025 · strength 0.47
  20. Kim C. Honselmann · 4 shared papers, 2017–2025 · strength 0.45
  21. Yoko Matsuda · 4 shared papers, 2019–2021 · strength 0.43
  22. Marta Sandini · 3 shared papers, 2020–2025 · strength 0.43
  23. David P. Ryan · 5 shared papers, 2011–2023 · strength 0.41
  24. Tayyaba Hasan · 2 shared papers, 2022–2024 · strength 0.38
  25. Shazia Bano · 2 shared papers, 2022–2024 · strength 0.38

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.